Search Results
Apr 21, 2026, 21:59 ET Chicago Rivet and Machine Co. Announces Annual Meeting of Shareholders and Provides Update on its Annual Report Filing
WARRENVILLE, Ill., April 21, 2026 /PRNewswire/ -- Chicago Rivet & Machine Co. (NYSE American: CVR) (the "Company") announces that its 2026 Annual Meeting of Shareholders will be held at the Sheraton Lisle Hotel, 3000 Warrenville Road, Lisle,
More news about: Chicago Rivet & Machine Co.
Apr 20, 2026, 06:30 ET AGNICO EAGLE TO CONSOLIDATE FINLAND'S CENTRAL LAPLAND GREENSTONE BELT IN THREE SEPARATE TRANSACTIONS
common share of Agnico Eagle ("Agnico Shares"); and (ii) contingent consideration of up to $3.00, in the form of a contingent value right ("CVR") that is payable, in cash, upon Rupert's properties reaching specified milestones (set out in detail below). The aggregate upfront consideration
More news about: Agnico Eagle Mines Limited
Mar 31, 2026, 06:45 ET Lilly to acquire Centessa Pharmaceuticals to advance treatments for sleep-wake disorders
plus one non-transferrable contingent value right (CVR) that entitles the holder to receive up to an aggregate of $9.00 subject to the achievement of three milestones described below, for total potential aggregate per share consideration of up to $47.00. CVR holders would become entitled to receive contingent
More news about: Eli Lilly and Company
Mar 30, 2026, 12:25 ET Shareholder Alert: The Ademi Firm investigates whether Kezar Life Sciences, Inc. is obtaining a Fair Price for Public Shareholders
no cost or obligation to you.In the transaction, Kezar stockholders will receive $6.955 in cash per share plus one contingent value right (CVR). The CVR provides rights to potential payments from the clinical development of zetomipzomib, proceeds from Kezar's collaboration with Everest Medicines
More news about: Ademi LLP
Mar 24, 2026, 17:00 ET Chicago Rivet & Machine Co. Announces Year-End Results of Operations
WARRENVILLE, Ill., March 24, 2026 /PRNewswire/ -- Chicago Rivet & Machine Co. (NYSE American: CVR) today announced audited results for the year 2025 as summarized below:
More news about: Chicago Rivet & Machine Co.
Mar 13, 2026, 01:05 ET transcosmos helps Wacoal build and operate e-commerce websites for Asian markets
process while optimizing costs. The new websites have already achieved tangible results shortly after launch, including an approximately 40% increase in CVR and a new purchaser rate of about 70% in Vietnam.
More news about: transcosmos inc.
Mar 10, 2026, 06:59 ET Q32 Bio Reports Fourth Quarter 2025 Financial Results and Provides Corporate Update
CVR liability
More news about: Q32 Bio
Feb 25, 2026, 08:00 ET Icahn Enterprises L.P. (Nasdaq: IEP) Today Announced Its Fourth Quarter and Full Year 2025 Financial Results
$ 2,703 CVR Energy(2)1,791
More news about: Icahn Enterprises L.P.
Feb 24, 2026, 13:41 ET /C O R R E C T I O N -- Chicago Rivet & Machine Co./
WARRENVILLE, Ill., Feb. 23, 2026 /PRNewswire/ -- Chicago Rivet & Machine Co. (NYSE American: CVR) today announced that its Board of Directors declared a quarterly cash dividend of $0.03 per share payable March 20, 2026, to all shareholders of record
More news about: Chicago Rivet & Machine Co.
Feb 18, 2026, 10:30 ET eVTOL Aircraft Market to Reach US$ 8,079.7 Billion by 2033 as Urban Air Mobility and Innovation Drive Demand | PMR
Flight Data Recorder (FDR) Market by Product Type (Cockpit Voice Recorder (CVR), Flight Data Recorder (FDR)), Aircraft Type (Wide Body, Narrow Body, Turboprop, General Aviation & Business Jets, Rotorcrafts), Application (Civil,
More news about: Persistence Market Research Pvt. Ltd.
Feb 12, 2026, 07:00 ET NewcelX Reports Peer-Reviewed Publication Supporting Mazindol IR/SR and Advances CVR Monetization Strategy
publication represents a significant inflection point in the strategic positioning of Mazindol ER under NewcelX's Contingent Value Right (CVR) framework pursuant to which CVR holders have the right to additional payments based on the proceeds received by NewcelX in the event of the disposition of certain legacy
More news about: NewcelX Ltd.
Feb 11, 2026, 09:00 ET Investindustrial Completes Acquisition of TreeHouse Foods
are entitled to receive $22.50 per share in cash for each share of common stock owned, and one non-transferable contingent value right ("CVR") per common share. The CVR provides a holder with an opportunity to receive certain net proceeds, if any are recovered, from the ongoing TreeHouse Foods, Inc.
More news about: TreeHouse Foods, Inc.
Jan 07, 2026, 14:50 ET TreeHouse Foods Investor Alert: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of TreeHouse Foods, Inc. - THS
Under the terms of the proposed transaction, shareholders of TreeHouse will receive $22.50 in cash and one non-transferable Contingent Value Right ("CVR") for each share of TreeHouse that they own. KSF is seeking to determine whether this consideration and the process that led to it are adequate, or whether
More news about: Kahn Swick & Foti, LLC
Dec 15, 2025, 07:50 ET TuHURA Biosciences Announces its Release of Kintara's Contingent Value Right (CVR) as Kintara's REM-001 Meets Primary Safety Endpoint Achieving Contractual Milestone
entitled to receive shares of TuHURA common stock, subject to the terms of the CVR Agreement and any applicable withholding. Pursuant to the CVR Agreement, the shares of TuHURA common stock are expected to be distributed to the CVR holders within the next ten business days. About TuHURA Biosciences,
More news about: TuHURA Biosciences, Inc.
Dec 12, 2025, 16:42 ET Mersana Therapeutics Investor Alert By The Former Attorney General Of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Mersana Therapeutics, Inc. - MRSN
shareholders of Mersana will receive $25.00 per share in cash plus one non-tradable contingent value right (CVR) per share to receive certain potential milestone payments of up to $30.25 per CVR in cash, for total consideration of up to $55.25 per share in cash. KSF is seeking to determine whether this
More news about: Kahn Swick & Foti, LLC
Dec 09, 2025, 08:28 ET Lilly and Adverum announce expiration and completion of Adverum tender offer and acquisition
applicable tax withholding, plus (ii) one non-tradable contingent value right ("CVR") per Share, which represents the contractual right to receive up to two contingent cash payments of up to an aggregate of $8.91 per CVR, net to the stockholder in cash, without interest and less any applicable tax withholding,
More news about: Eli Lilly and Company
Dec 08, 2025, 14:40 ET $HAREHOLDER ALERT: The M&A Class Action Firm Continues to Investigate the Merger--SMLR, MRSN, CDTX, and RYI
transaction, Mersana shareholders will receive $25.00 per share in cash plus one non-tradeable contingent value right ("CVR") per share to receive certain milestone payments of up to $30.25 per CVR in cash, for total consideration of up to $55.25 per share in cash.ACT NOW. The Tender Offer expires
More news about: Monteverde & Associates PC
Nov 27, 2025, 23:11 ET HAPPY THANKSGIVING AND INVESTOR ALERT: The M&A Class Action Firm Continues to Investigate the Merger - EXAS, SEE, CDTX, and MRSN
transaction, Mersana shareholders will receive $25.00 per share in cash plus one non-tradeable contingent value right ("CVR") per share to receive certain milestone payments of up to $30.25 per CVR in cash, for total consideration of up to $55.25 per share in cash. Is it a fair deal?Click
More news about: Monteverde & Associates PC
Nov 25, 2025, 10:01 ET Veterinary Reference Laboratory Market worth US$6.46 billion by 2030 with 6.3% CAGR | MarketsandMarkets™.
Laboratory (Canada), Vaxxinova (Germany), Mira Vista Labs (US), Ellie Diagnostics (Germany), Protatek International, Inc. (US), The Pirbright Institute (UK), CVR Laboratory (CVRL) (UAE), Veterinary Pathology Group (UK), , and Friedrich-Loeffler-Institut (Germany).IDEXX Laboratories, Inc. (US):IDEXX
More news about: MarketsandMarkets
Nov 25, 2025, 01:00 ET Fisher Investments anerkendes som et "Great Place to Work®"
globale Fisher-koncern. Fisher Investments Norden er registreret hos det danske finanstilsyn og i det danske selskabsregister, Erhvervsstyrelsen, under CVR-nr. 41000643. Selskabets hjemstedsadresse er: København Ørestad Winghouse, Ørestads Boulevard 73, 2300 København S, Danmark. Den danske filial af Fisher
More news about: Fisher Investments Norden
Nov 19, 2025, 18:18 ET Halper Sadeh LLC Encourages BRNS, FITB, ADVM, HBAN Shareholders to Contact the Firm to Discuss Their Rights
transaction, Adverum shareholders will receive $3.56 per share in cash plus one non-transferrable contingent value right (CVR) entitling the holder to receive up to an additional $8.91 per CVR in cash upon the achievement of two certain milestones. If you are an Adverum shareholder,
More news about: Halper Sadeh LLP
Nov 19, 2025, 14:10 ET $HAREHOLDER ALERT: The M&A Class Action Firm Continues to Investigate the Mergers-HOUS, ADVM, HBAN, and COMP
transaction, Adverum shareholders will receive $3.56 per share in cash plus one non-transferable contingent value right ("CVR") entitling the holder to receive up to an additional $8.91 per CVR in cash upon the achievement of two certain milestones.
More news about: Monteverde & Associates PC
Nov 19, 2025, 06:00 ET Alkermes plc Announces Increased Offer to Acquire Avadel Pharmaceuticals plc
one (1) non-transferable contingent value right ("CVR") entitling holders to a potential additional cash payment of $1.50 per share, contingent upon final U.S. Food and Drug Administration ("FDA") LUMRYZ™ Approval (as defined in the form of CVR agreement to be entered into by Alkermes and
More news about: Alkermes plc
Nov 18, 2025, 11:38 ET CHICAGO RIVET & MACHINE CO. DECLARES DIVIDEND
WARRENVILLE, Ill., Nov. 18, 2025 /PRNewswire/ -- Chicago Rivet & Machine Co. (NYSE American: CVR) today announced that its Board of Directors declared a quarterly cash dividend of $0.03 per share payable December 19, 2025, to all shareholders of
More news about: Chicago Rivet & Machine Co.
Nov 14, 2025, 19:56 ET Shareholder Alert: The Ademi Firm investigates whether Repare Therapeutics Inc. is obtaining a Fair Price for its Public Shareholders
after deducting transaction costs and outstanding liabilities. Additionally, shareholders will receive one non-transferable contingent value right (CVR) per share, entitling them to portions of future proceeds from existing partnerships and potential asset dispositions. The CVRs provide varying percentages
More news about: Ademi LLP